

# Contents

## Part I Strategy and Tactics that Enable Discovery

- 1 Developability Assessment and Risk Management During Drug Discovery . . . . . 3**  
Sudhakar Garad and Akash Jain
- 2 Discovery Formulations: Approaches and Practices in Early Preclinical Development . . . . . 49**  
Shobha N. Bhattachar, David M. Bender, Stephanie A. Sweetana, and James A. Wesley
- 3 Enabling Discovery Through Leveraging and Miniaturizing Pharmaceutical Principles and Processes . . . . . 95**  
Roy J. Haskell, Kimberly A. Foster, Ching Kim Tye, and Michael Morgen
- 4 Diagnosing Biopharmaceutical Limitations . . . . . 141**  
Susan M. Jenkins and Dawn D. Parker
- 5 The Importance of Molecular Design Principles in Delivering High Quality Pharmaceutical Candidates . . . . . 177**  
Thomas E. Prisinzano

## Part II Predictive Approaches to Establishing, Understanding, and Communicating Risk in Early Development

- 6 Predictive Approaches to Establishing, Understanding, and Communicating Risk with Emphasis on Early Development . . . . . 195**  
Stephen R. Byrn
- 7 Strategies and Methods for Drug Candidate Phase Optimization in Discovery Space . . . . . 209**  
Michael McNevin and John Higgins

<b>8</b>	<b>Efficient Laboratory Methods to Assess Risk and Design Formulations . . . . .</b>	<b>241</b>
	Stephen R. Byrn and Roy J. Haskell	
<b>9</b>	<b>Advanced X-Ray Analytical Methods to Understand Structure, Properties, and Risk . . . . .</b>	<b>263</b>
	C.J. Benmore	
 <b>Part III Use of Physicochemical Properties for Preclinical Formulation Selection and Early Clinical Formulations</b>		
<b>10</b>	<b>Performance and Characterization of Amorphous Solid Dispersions: An Overview . . . . .</b>	<b>287</b>
	Grace Ilevbare, Patrick Marsac, and Amitava Mitra	
<b>11</b>	<b>Hot-Melt Extrusion: The Process-Product-Performance Interplay . . . . .</b>	<b>345</b>
	Nathan Boersen, Chad Brown, James DiNunzio, David Johnson, Patrick Marsac, Robert Meyer, and Craig McKelvey	
<b>12</b>	<b>Practical Considerations for Spray Dried Formulation and Process Development . . . . .</b>	<b>383</b>
	Michael Lowinger, John Baumann, David T. Vodak, and Justin Moser	
<b>13</b>	<b>Nanosizing: “End-to-End” Formulation Strategy for Poorly Water-Soluble Molecules . . . . .</b>	<b>437</b>
	Elaine Merisko-Liversidge	
<b>14</b>	<b>Leveraging Solid State Form and Physiochemical Properties for Early Clinical Formulation Efforts: Opportunities and Challenges During Telcagepant Liquid Capsule Development . . . . .</b>	<b>469</b>
	Dan Zhang, Allen C. Templeton, William Marinaro, Alfred C.F. Rumondor, Filippas Kesisoglou, Brett Duersch, Karen Thompson, Joyce Stellabott, and Michael H. Kress	
	<b>Index . . . . .</b>	<b>509</b>

Discovering and Developing Molecules with Optimal  
Drug-Like Properties

Templeton, A.C.; Byrn, S.R.; Haskell, R.J.; Prisinzano,  
Th.E. (Eds.)

2015, XI, 511 p. 161 illus., 130 illus. in color., Hardcover

ISBN: 978-1-4939-1398-5